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AbstrAct
Introduction Fatigue is a frequent and troublesome 
manifestation of chronic sarcoidosis. This symptom can 
be debilitating and difficult to treat, with poor response 
to the treatment. Symptomatic management with 
neurostimulants, such as methylphenidate, is a possible 
treatment option. The use of such treatment strategies 
is not without precedent and has been trialled in cancer-
related fatigue. Their use in sarcoidosis requires further 
evaluation before it can be recommended for clinical 
practice.
Methods and analysis The Fatigue and Sarcoidosis—
Treatment with Methylphenidate study is a randomised, 
controlled, parallel-arm and feasibility trial of 
methylphenidate for the treatment of sarcoidosis-
associated fatigue. Patients are eligible if they have a 
diagnosis of sarcoidosis, significant fatigue (measured 
using the Fatigue Assessment Scale) and have stable 
disease. Up to 30 participants will be randomly assigned 
to either methylphenidate (20 mg two times per day) or 
identical placebo in a 3:2 ratio for 24 weeks. The primary 
objective is to collect data determining the feasibility of a 
future study powered to determine the clinical efficacy of 
methylphenidate for sarcoidosis-associated fatigue. The 
trial is presently open and will continue until July 2018.
Ethics and dissemination Ethical approval for the study 
was granted by the Cambridge Central Research Ethics 
Committee on 21 June 2016 (reference 16/EE/0087) 
and was approved and sponsored by the Norfolk and 
Norwich University Hospital (reference 190280). Clinical 
Trial Authorisation (EudraCT number 2016-000342-60) 
from the Medicines and Healthcare products Regulatory 
Agency (MHRA) was granted on 19 April 2016. Results will 
be presented at relevant conferences and submitted to 
appropriate journals following trial closure and analysis.
trial registration number NCT02643732; Pre-results.
IntroductIon
Sarcoidosis is a granulomatous, multisystem 
disease with an incidence of 5 per 1 00 000 
person–years, typically affecting patients of 
working age.1 Fatigue has been described as 
a ‘core symptom’ of sarcoidosis and is present 
in up to 80% of patients.2 3 The presence of 
fatigue has shown to adversely affect quality 
of life.4 Sarcoidosis-associated fatigue has 
multiple possible aetiologies. These include 
subclinical disease activity,5 increased circu-
lating tumour necrosis factor-alpha levels,6 
disturbed circadian rhythm7 and sleep,8 
small-fibre neuropathy,9 depression,10 
sleep-disordered breathing problems,11 treat-
ment-related side effects12 or a combination 
of any of these factors.
role of neurostimulants in treating fatigue
Current evidence for treatments of sarcoid-
osis-associated fatigue is weak, with further 
work required.13 The use of methylpheni-
date for fatigue is not without precedent, 
having been trialled in cancer-related 
fatigue and recommended as effective for 
symptomatic relief after meta-analysis by 
the Cochrane collaboration.14 There is also 
evidence for effect in fatigue associated 
with Parkinson’s disease15 and HIV.16 In all 
Feasibility study of a randomised 
controlled trial to investigate the 
treatment of sarcoidosis-associated 
fatigue with methylphenidate (FaST-
MP): a study protocol
Christopher Atkins,1,2 Richard Fordham,1 Allan B Clark,1 Andrea Stockl,1 
Andrew P Jones,1 Andrew M Wilson1,2
To cite: Atkins C, Fordham R, 
Clark AB, et al.  Feasibility study 
of a randomised controlled trial 
to investigate the treatment of 
sarcoidosis-associated fatigue 
with methylphenidate (FaST-
MP): a study protocol. BMJ Open 
2017;7:e018532. doi:10.1136/
bmjopen-2017-018532
 ► Prepublication history for 
this paper is available online. 
To view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2017- 
018532).
Received 5 July 2017
Revised 25 October 2017
Accepted 8 November 2017
1Department of Medicine, 
University of East Anglia Norwich 
Medical School, Norwich, 
Norfolk, UK
2Department of Respiratory 
Medicine, Norfolk and Norwich 
University Hospital, Norwich, 
Norfolk, UK
correspondence to
Dr Christopher Atkins;  
 c. atkins@ uea. ac. uk
Protocol
strengths and limitations of this study
 ► Twenty-four-week duration of receiving 
methylphenidate or placebo.
 ► Variety of outcome measures included to inform 
future study design.
 ► Exercise measurements during study done both in 
clinic (modified shuttle walk test) and using objective 
measures of exercise during free-living (wrist-worn 
activity monitors).
 ► Small participant numbers will not prove clinical 
efficacy of methylphenidate but does allow 
appropriate future study design to be determined.
 ► No stratification for age or sex due to small number 
of participants.
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cases, the treatment has only been trialled for a short 
period of time (up to 12 weeks). Neurostimulants 
have been trialled for symptomatic relief of fatigue 
associated with sarcoidosis. Both methylphenidate17 
and modafinil18 have been trialled in patients with 
significant fatigue, though in only a very small sample 
(10 patients trialled methylphenidate and 15 trialled 
modafinil) over only 8 weeks, a period of time that 
does not reflect the typical period of time that these 
agents may be used for in clinical practice. Despite 
initial evidence for the use of methylphenidate in 
sarcoidosis-associated fatigue being published almost 
10 years ago, no further studies have been published; 
the reasons for this are unclear when sarcoidosis-as-
sociated fatigue remains a significant clinical issue 
without established treatment strategies. Questions 
remain about ongoing treatment effect, side effects 
during protracted treatment and whether patients 
would continue to take the medication over a longer 
period. For these reasons, this feasibility study has 
been undertaken prior expanding to a large, multi-
centre randomised controlled trial (RCT).
rationale for this pilot trial
High quality evidence is required to establish the clinical 
efficacy and long-term tolerability of methylphenidate for 
the treatment of sarcoidosis-associated fatigue. Change 
in fatigue scores measured by a validated questionnaire 
measure of fatigue across a longer treatment period of 
6 months would be able to address the issue of efficacy, 
but the evidence to support a large-scale RCT, or deter-
mine the optimal design of such an RCT, is presently 
insufficient.
Furthermore, although recommendations from the 
World Association of Sarcoidosis and Other Gran-
ulomatous diseases recommend measuring fatigue 
in trials involving patients with sarcoidosis using a 
validated questionnaire,19 we also plan to investi-
gate the effect on activity levels with treatment using 
wrist-worn accelerometers alongside typical question-
naire measures. Outputs from these activity monitors 
appear to correlate with fatigue scores, both in terms 
of reduced activity and increased time in sedentary 
behaviours (C Atkins, unpublished data, 2016), and 
may give further insight into how improvements in 
fatigue affect day-to-day living in patients. To plan a 
sufficiently large RCT, we propose a pilot placebo-con-
trolled RCT to inform the design of a future, definitive 
trial investigating the management of fatigue.
objEctIvEs
The primary hypothesis is to determine the feasibility and 
design of a future, large-scale RCT investigating the use 
of methylphenidate to treat sarcoidosis-associated fatigue 
and provide sustained benefit over a 6-month period. In 
addition, it will pilot the use of wrist-worn, triaxial accel-
erometer-based activity monitors to monitor change in 
activity and sedentary behaviours during the treatment 
alongside validated questionnaire-based fatigue scores.
MEthods
Participants
This study is a randomised, double-blind, placebo-con-
trolled single-centre parallel-group trial with randomis-
ation of up to 30 patients in a ratio of 3:2 in favour of 
methylphenidate. This unequal arm size will increase 
data collected from the treatment arm, including 
adverse event rates. The trial is currently taking place at 
a single tertiary centre (Norfolk and Norwich University 
Hospital (NNUH), UK) and will remain open until July 
2018. Participants are identified through the respiratory 
clinic at the NNUH. The intervention is methylpheni-
date, initially 10 mg two times per day and increased to 
20 mg two times per day, if appropriate, compared with 
an identical placebo. Participants and outcome asses-
sors are blinded to the treatment received. Allocation is 
through an on-line system which allocates participants to 
methylphenidate or placebo and automatically informs 
the hospital pharmacy of the group allocated to allow 
dispensing of treatment while maintaining blinding. 
Participant flow through the trial is shown in figure 1.
Study participants are required to attend eight clin-
ical visits over a 26-week period; one screening visit, a 
review at baseline, assessments for side effects at 2 and 
4 weeks, assessment of clinical outcomes at 6, 12, 18 and 
24 weeks. There is one post-trial assessment 6 weeks after 
discontinuing. Between visits, participants are contacted 
by phone call to monitor for side effects. Study visits and 
activities take place at the NNUH, although patients 
treated by other hospitals in the East of England region 
can be recruited if their centre is willing to act as a Partic-
ipant Identification Centre (PIC site) and participants 
are willing to travel to the NNUH. The overview of study 
visits, including the assessments performed, is shown in 
table 1.
All participants must have a diagnosis of sarcoidosis. 
The full list of inclusion and exclusion criteria are shown 
in box 1. All eligible participants with sarcoidosis and 
fatigue (defined as a Fatigue Assessment Scale (FAS) score 
more than 21) who are invited to participate in the study 
are provided with written information. Participants who 
agree to participate are required to give written informed 
consent. Initial contact with participants is during their 
attendance at the respiratory outpatient department or 
following referral from the patient’s primary respiratory 
physician.
Interventions
A screening visit occurs 2 weeks prior to commencing 
study medications. This visit is used to collect written 
informed consent, baseline demographic data, list 
current medications (including current and prior treat-
ment for sarcoidosis), measure blood pressure, pulse and 
perform a baseline ECG and blood tests (renal function 
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Figure 1 Patient flow through trial. FBC, full blood count; LFT, liver function test; PIS, patient information sheet; TFT, thyroid 
function test; U&E, urea and electrolytes.
and electrolytes, liver function and full blood count). 
Female participants undertake a pregnancy test. Clinical 
data are reviewed for manifestations of sarcoidosis, to 
determine whether extra pulmonary disease is present. 
Fatigue is quantified by FAS questionnaire; all participants 
must have a baseline FAS score of more than 21 points to 
participate. Obstructive sleep apnoea (OSA) is screened 
for using the STOP-Bang Questionnaire. Participants 
scoring above 4 points undergo overnight pulse oximetry 
to determine if OSA is present, those with a desaturation 
index of >15 being excluded and referred for consider-
ation of the treatment. Finally, potential participants wear 
an activity monitor (GENEActiv Original; Activinsights, 
Cambridgeshire, UK) on their non-dominant wrist for 
a 7-day period to measure daily activity levels prior to 
commencing therapy. Once baseline fatigue, comorbid-
ities, medications and blood tests have been checked to 
confirm no contraindication to participation, the subject 
is randomised.
When participants have been confirmed as eligible for 
participation in the Fatigue and Sarcoidosis–Treatment 
with Methylphenidate (FaST-MP) study following their 
screening visit, they are invited back 2 weeks later to under-
take the baseline visit which records preintervention ques-
tionnaire scores and spirometry. At this visit, participants 
complete fatigue scores (FAS score and the Functional 
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box 1 Eligibility criteria
Inclusion criteria
 ► A proven diagnosis of sarcoidosis: this is defined as either a biopsy-
proven disease (non-caseating granulomas from a tissue biopsy) 
or a diagnosis of sarcoidosis agreed by an interstitial lung disease 
multidisciplinary team meeting.
 ► Stable disease (treatment unchanged for 6 weeks, without 
anticipation of change in treatment during trial period).
 ► Able to give informed consent.
 ► Fatigue Assessment Scale score greater than 21 units.
Exclusion criteria
 ► Evidence of coexisting obstructive sleep apnoea.
 ► Documented history of significant cardiac disease (including 
cardiac sarcoid) or associated disease which would increase risk 
of underlying coronary artery disease (cerebrovascular disease, 
previous stroke or peripheral vascular disease). Definitively treated 
cardiac disease, for example, previous myocardial infarction treated 
with stents or coronary artery bypass grafting with no ongoing 
symptoms is permitted.
 ► Abnormal thyroid function (hyperthyroidism or hypothyroidism).
 ► History of seizures, excluding febrile convulsions while an infant.
 ► Abnormal ECG with evidence of arrhythmia (except first degree 
heart block which has been stable for 3 months).
 ► Concomitant therapy with an excluded medication (see Concomitant 
therapies section).
 ► Glaucoma or raised intraocular pressure for any reason.
 ► Patients with established liver disease defined as Child-Pugh class 
B or C.
 ► Documented medical history of psychiatric disorders (excluding 
depression).
 ► History of drug dependence or addiction at any time.
 ► Female participant who is pregnant, lactating or planning pregnancy 
during the course of the trial.
 ► Receiving an investigational drug or biological agent within 6 weeks 
(or five times the half-life if this is longer) prior to study entry.
Assessment of Chronic Illness Therapy–Fatigue (FACIT-F) 
Questionnaire), quality of life scores (King’s Sarcoid-
osis Questionnaire (KSQ), EuroQoL-5D-5L (EQ5D) 
and Short Form-36 (SF-36) questionnaires), depression 
symptom screening (Hospital Anxiety and Depression 
Score (HADS) questionnaire), sleep quality (Pittsburgh 
Sleep Quality Index (PSQI) questionnaire) and a custom 
costs questionnaire for health economic analysis. In addi-
tion, participants perform a modified shuttle walk test 
(MSWT) to determine exercise capacity and perform 
spirometry to measure baseline lung function. After these 
assessments have been completed, participants receive 
their first 2-week supply of study medication, either meth-
ylphenidate 10 mg two times per day or matched placebo.
The visit schedule over the first 6 weeks focuses on 
safety and adverse events, plus establishing a stable dose. 
After 1 week of therapy, participants receive a phone call 
from the study team to review potential adverse effects 
from the medication. A further week later, the participant 
is seen for their first follow-up visit with safety measures 
taken (full blood count, renal function and liver function 
plus ECG) and review of side effects. If no adverse events 
group.bmj.com on December 21, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
6 Atkins C, et al. BMJ Open 2017;7:e018532. doi:10.1136/bmjopen-2017-018532
Open Access 
box 2 Primary and secondary outcomes
Primary outcome: Feasibility assessments
 ► Recruitment rate and retention of participants.
 ► Reason for exclusion or withdrawal from the study.
 ► Number of participants suffering side effects or requiring reduction 
of methylphenidate dose due to emergence of side effects and the 
dose tolerated by greatest proportion of participants.
 ► Indication(s) of continuation of effect at stable dose during 
the treatment period.
 ► Number of patients correctly using accelerometers.
 ► Acceptability of number of study visits and assessments.
 ► Acceptability of randomisation.
 ► Acceptability of receiving a controlled drug.
 ► Mean change in fatigue score and SD of change (for subsequent 
power calculations).
 ► Patient perception of trial involvement (focus groups and exit 
questionnaire).
secondary outcomes: Exploratory assessment of clinical 
effects of methylphenidate over 24 weeks
 ► Change in fatigue scores—Fatigue Assessment Scale and Functional 
Assessment of Chronic Illness Therapy-Fatigue.
 ► Disease-specific quality of life—Kings Sarcoidosis Questionnaire.
 ► Depression and anxiety—Hospital Anxiety and Depression Scale.
 ► Generic quality of life—EuroQoL-5D-5L and Short Form-36.
 ► Usage of health and social care — cost questionnaire.
 ► Sleep quality—Pittsburgh Sleep Quality Index; augmented with 
results from wrist-worn accelerometer data (awakenings).
 ► Modified shuttle walk test distance—number of shuttles completed.
 ► Physical activity in free-living—mean accelerometer output (most 
active 5 hours, time in moderate or vigorous activity  and time in 
sedentary behaviours).
 ► Lung function—spirometry (forced expiratory volume in 1 s and 
forced vital capacity).
have been identified then participants are titrated up to 
the higher dose of 20 mg methylphenidate two times per 
day if there has been insufficient clinical improvement in 
fatigue. Further safety visits (via phone on weeks 3 and 
5, and with the study team for blood tests and ECG at 
week 4) subsequently occur; in the event of side effects 
emerging participants may be down-titrated to 10 mg 
methylphenidate two times per day (see Discontinuation 
criteria section for more details).
At 6 weeks, participants return for a further safety visit, 
undergoing the same blood tests and a repeat ECG. In 
addition, the study questionnaires are repeated (FAS, 
FACIT-F, KSQ, EQ5D, SF-36 and HADS), with the excep-
tion of the costs questionnaire which is performed at 12 
and 24 weeks. Participants continue to receive phone calls 
to monitor for side effects every 2 weeks but are next seen 
face to face at 12 weeks, where all measures (safety bloods 
and ECG, adverse events, questionnaires including costs 
and PSQI, MSWT and spirometry) are repeated. In addi-
tion, participants wear a wrist-worn accelerometer for a 
further 7 days to review daily activity levels and answers 
questions on sleep quality.
A further visit is undertaken at 18 weeks where partic-
ipants undergo the same investigations as at 6 weeks, 
and finally again at 24 weeks where all study assessments 
are repeated, including an additional exit questionnaire 
collecting information about experiences of the trial 
and the medication. Participants on the higher dose of 
methylphenidate (20 mg two times per day) are reduced 
to 10 mg two times per day for 2 weeks; participants who 
complete the study on the lower dose discontinue all 
study medications at 24 weeks.
Following discontinuation of the study medication 
participants will undertake all questionnaires, excluding 
the cost questionnaire, and be assessed for side effects 
6 weeks after discontinuing medications (30 weeks after 
commencing study medications). This will allow investiga-
tion of whether fatigue returns to baseline level following 
discontinuation of medication, or whether any benefit 
compared with baseline persists.
All participants are asked at the point of consenting 
to enter the study whether they would be willing to be 
approached about participating in focus groups following 
their completion of the study. Those who agree are offered 
the option to participate in focus groups following the 
completion of their trial participation; this is to investi-
gate their experience and perception of the trial. There is 
a standardised topic guide to direct discussions (available 
from the authors). All data are audio recorded and then 
transcribed. It is not a mandatory part of the study; we 
aim to have three groups of six to eight participants at 
completion of the study.
outcomes
Primary and secondary outcomes are listed in box 2. Data 
collection points for each of the outcome measures are 
shown in table 1. The primary outcomes are related to 
feasibility, based on recruitment (including number of 
patients who are eligible to participate), the number of 
participants that are retained at each point of the study, 
the number of participants providing data through to the 
end of the trial and an estimate of treatment effect using 
change in the fatigue score measurements (FAS and 
FACIT-F) between methylphenidate and placebo groups 
which will influence future power calculations.
The output from this trial will influence the choice of 
primary outcome for future trials investigating sarcoid-
osis-associated fatigue. This is likely to be the FAS ques-
tionnaire as it is both symptom-specific for fatigue and 
has been validated in sarcoidosis cohorts previously.20 
However, the interaction between changes in fatigue 
scores (both FAS and FACIT-F) and other measures, 
including depression and anxiety (HADS) and quality of 
life (KSQ, EQ5D and SF-36), will be reviewed to deter-
mine how these measures change longitudinally with 
change in fatigue.
Additionally, a cost questionnaire will be adminis-
tered to all participants. This is a custom-made instru-
ment being piloted in this study which will look at costs 
incurred on a day-to-day basis by participants, including 
changes in out-of-pocket costs to participants relating 
to their health, health service usage and employment/
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working time. These methods can then be amended as 
required for appropriate cost estimation in a definitive 
trial in the future.
concomitant therapies
Participants are able to receive any immunosuppres-
sant drugs that would treat their sarcoidosis, but they 
are required to be on a stable dose of their medication 
for 6 weeks prior to study enrolment with no planned 
change in dose during the trial. In the event that treat-
ment is altered, either reducing or increasing the dose 
of existing therapy or starting additional medication for 
their sarcoidosis, this is recorded in their case report file.
There are a number of drugs which are contraindi-
cated when receiving methylphenidate due to the risk of 
side effects; participants are not permitted to receive these 
during the trial. These include any tricyclic antidepressant 
(TCAs); any monoamine oxidase inhibitor (MAOI); all 
antipsychotics; sympathomimetics including phenyleph-
rine, ephedrine or pseudoephedrine; buprenorphine; 
tramadol; levodopa; clonidine; methylene blue; warfarin. 
Although both TCAs and MAOIs are prohibited, selec-
tive serotonin inhibitors are allowed and have been used 
alongside methylphenidate safely previously.21
safety considerations
Methylphenidate is associated with side effects due to 
cardiac, neurological or psychiatric effects. The trial has 
been designed to minimise the risk of these complica-
tions occurring while receiving methylphenidate, both 
through the exclusion criteria and the visit schedule with 
safety monitoring. Cardiac side effects are screened for 
at baseline with ECG monitoring, and at every study visit 
thereafter. Any development of cardiac complications 
or ECG abnormalities, even if clinically asymptomatic, 
results in discontinuation of the study medication. Neuro-
logical and psychiatric problems are screened for, with 
any history of seizures (aside from febrile convulsions 
during childhood) or psychiatric disease (except depres-
sion) preventing patients from participating in the trial. 
Participants who are included in the trial are monitored at 
each visit for the emergence of any side effects, including 
seizures, abnormal behaviour or personality change.
A final safety consideration relates to methylphenidate 
being a controlled drug. The potential illicit use of meth-
ylphenidate risks participants selling or giving away medi-
cations to others. All participants will be informed about 
the illegal nature of these activities, and asked to sign a 
document to indicate their understanding and agree-
ment. Medication prescriptions are initially for 2 weeks, 
increased to 6 weeks after the third visit (at 6 weeks) with 
participants bringing their remaining supply of medica-
tion to each visit for pill-count checking.
discontinuation criteria
Immediate discontinuation will occur, regardless of the 
present dose, if participants develop a generalised rash 
or pruritus considered to be related to the intervention, 
develops an abnormality on ECG, suffers chest pain consis-
tent with angina, experiences severe anxiety or euphoria, 
personality change or bizarre behaviour or if any psychi-
atric disease manifests during the trial. Other reasons for 
immediate discontinuation are seizures and severe hyper-
tension (defined as a systolic blood pressure >180 mm Hg 
on two separate occasions or presenting with any features 
of malignant hypertension). Side effects which will lead 
to down-titration of the study drug in the first instance 
(if the participant is receiving the higher dose of 20 mg 
methylphenidate two times per day) include nervousness 
or restlessness, significant nausea or indigestion, nasal 
stuffiness, cough, arthralgia or anorexia. Participants can 
also choose to discontinue the study medication at any 
time for any reason. In consenting to the trial participants 
are agreeing to trial treatments, trial follow-up and data 
collection, including storage of anonymised data within a 
dataset available to other researchers from a data reposi-
tory at the end of the trial.
sample size and recruitment
The sample size of 30 patients was chosen in order to 
answer questions regarding recruitment, number of 
eligible participants and reasons for exclusion and to 
pilot some elements of the trial, including the use of 
accelerometers measuring activity levels as part of the 
outcomes. This also ensures a minimum of 12 partici-
pants per group as per recommendations.22 This study 
is not powered to identify clinical efficacy, although 
an estimation of effect size between methylpheni-
date and placebo will enable power calculations to be 
performed for any future follow-on studies investigating 
methylphenidate.
All research activities occur at a single tertiary hospital 
site, although within this study we are using PICs to 
improve recruitment by enabling a wider number of 
patients to be considered for inclusion within this study.
data management and monitoring
A purpose-designed, secure password-protected elec-
tronic case report form is used for data entry throughout 
the trial, complying with data protection requirements 
on confidentiality and anonymity. The database enables 
screened patients to be randomised, linking with the 
local hospital pharmacy to securely randomise patients 
via email. This maintains blinding of the clinical team, 
research team and investigators and patients. Allocation 
is determined based on block randomisation in blocks of 
five with stratification by severity of fatigue (FAS 22–34 
and FAS 35–50). The system is managed by the Norwich 
Clinical Trials Unit and can only be accessed by the chief 
investigator or appropriate members of the study team 
with delegated responsibility.
Throughout the trial monitoring will occur quarterly, 
carried out locally with oversight from the clinical trials 
unit and sponsor. A trial steering committee and safety 
committee monitor trial performance and adverse events. 
The two groups meet 6 monthly and may terminate the 
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trial if significant concerns become apparent, although 
formal stop criteria have not been set.
data analysis
Initial data analysis will evaluate prespecified feasibility 
criteria. First, a recruitment rate of 10% from our local 
sarcoidosis cohort is required to meet our recruitment 
aims; in the event of lower recruitment rates then 
consideration will need to be given to the ability to 
recruit the necessary number of sites, although this will 
be determined by the estimate of the mean difference in 
fatigue scores (effect size). The mean difference will be 
estimated using a general linear model for continuous 
outcomes, with an emphasis on estimation rather than 
hypothesis testing. Analysis will be based on an intention-
to-treat approach. Adverse event data will be tabulated 
by category per group. No formal comparison will be 
made. Previous trails of methylphenidate have suggested 
an adverse events rate of less than 5% but these have not 
used the drug for more than 12 weeks (8 weeks in the 
previous trial involving patients with sarcoidosis-associ-
ated fatigue17). An adverse event rate of more than 10% 
during this 24-week trial would trigger consideration of 
the safety of methylphenidate for longer periods and 
the suitability of using this agent. Finally, previous trials 
have managed a retention rate of more than 80% of 
participants; we will review the retention rate over this 
longer trial, aiming for over 60% retention to suggest a 
larger trial over such a period would be feasible. Under-
standing whether the other clinical measures being 
employed here (including the MSWT and accelerom-
eter measure of activity) are responsive to changes in 
fatigue scores, and therefore worth including in subse-
quent trials, will determine if they should be included in 
future studies.
Power calculations for any subsequent trial will be 
performed using the data from change in the FAS score, 
which will inform sample size requirements, as well as 
data on drop-out rates through the trial.
Participant perception of undertaking the trial will 
be reviewed using the discussions in the focus groups. 
Participant views on the number of study visits, the 
intervention received (including the fact that it is a 
controlled drug), the specific measures used including 
the MSWT and activity monitor, and overall impression 
of participating in the trial (both positive and negative) 
will be reviewed following the focus groups, which will 
act as a debrief session for participants. This qualitative 
process evaluation has been recommended for use in 
the development of some RCTs and will enable opti-
misation of a future RCT through the experiences of 
participants.23
Exploratory analysis of the data will take place to inves-
tigate whether any change in fatigue or other measures 
is seen during the trial between groups, with appropriate 
adjustment for baseline values. The study is not powered 
for these clinical outcomes; this will be clearly stated in 
any outputs from these analyses.
study registration and approvals
Approval from the Medicines and Healthcare products 
Regulatory Agency (MHRA - EudraCT reference number 
2016-000342-60) and Research Ethics Committee (REC 
- East of England; Cambridge Central, reference number 
16/EE/0087) has been gained, with the trial adopted 
by the Health Research Authority (HRA). The study has 
been registered on a clinical trial database (http:// clin-
icaltrials. gov), reference number NCT02643732 (pre-re-
sults). The study has been open for recruitment since 
October 2016 and will continue until July 2018.
dIscussIon
The FaST-MP study has been developed to inform deci-
sion-making regarding any future trial investigating the 
use of neurostimulants for the treatment of sarcoidosis-as-
sociated fatigue, a frequent and often challenging mani-
festation of chronic sarcoidosis. The results from this 
study will allow us to determine if progressing to a full-size 
trial using this drug is feasible, how many centres would 
be required, how the study would need to be structured 
and which outcome measures would be best employed 
to monitor progress throughout the trial. Piloting new 
outcome measures (costs questionnaire and activity moni-
tors) during the course of this RCT will also enable us to 
evaluate these measures and their suitability for future 
studies.
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